ENDRA Life Sciences Insider Award: 5,384 RSUs to Director Michael Harsh

Rhea-AI Filing Summary

On June 11, 2025, ENDRA Life Sciences (NDRA) director Michael Harsh received 5,384 restricted stock units (RSUs), as disclosed in a Form 4 filed on July 1, 2025. The RSUs carry an exercise price of $0 and convert to common stock on a one-for-one basis.

Vesting schedule: the entire award vests on June 11, 2026. After the grant, Harsh beneficially owns 5,386 NDRA common shares, held directly. No derivative instruments or share disposals were reported, and no cash changed hands.

This appears to be a routine equity-compensation grant designed to encourage long-term alignment between the director and shareholders. The transaction is too small to impact NDRA’s share count, earnings or liquidity, but it does marginally increase insider ownership.

Insights

Securities Analyst

TL;DR: Routine 5,384-share RSU grant; negligible financial impact, slight boost to insider alignment.

The filing shows a standard equity award to director Michael Harsh at no cost to the company other than dilution. Total beneficial ownership rises to 5,386 shares, an immaterial fraction of NDRA’s float, so market impact is minimal. Because no shares were sold, the signal is neutral-to-slightly positive for sentiment, but not material enough to shift valuation or liquidity considerations.

Corporate Governance Expert

TL;DR: One-year-vesting RSUs reinforce governance norms; no red flags detected.

Annual RSU grants with a one-year cliff are common for small-cap boards and promote director/shareholder alignment. The absence of accelerated vesting, option repricing, or 10b5-1 trading plans suggests a straightforward compensation action. Investors should view this as routine governance practice rather than a signal of strategic change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harsh Michael

(Last) (First) (Middle)

C/O ENDRA LIFE SCIENCES INC.

3600 GREEN COURT, SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2025		A		5,384(1)	A	$0	5,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

	/s/ Michael Harsh by Mark Busch, attorney-in-fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NDRA disclose in the latest Form 4?

ENDRA Life Sciences reported that director Michael Harsh was granted 5,384 RSUs on June 11, 2025, vesting on June 11, 2026.

How many NDRA shares does Michael Harsh now own?

After the RSU grant, Harsh beneficially owns 5,386 common shares, all held directly.

Was any cash paid for the RSU award?

No. The RSUs were issued at a $0 exercise price; the director did not pay cash for the shares.

When will the RSUs granted to NDRA’s director vest?

The entire RSU award will vest on June 11, 2026.

Does this insider transaction affect NDRA’s share count materially?

The issuance of 5,384 shares is immaterial relative to NDRA’s overall float and should not meaningfully affect dilution.